2016
DOI: 10.1021/acs.jmedchem.6b00055
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Poly(ADP-ribose)polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills cancer cells by targeting homologous recombination repair defects. Since 2010, important advances have been achieved in PARP-1 inhibitors. Specifically, the approval of olaparib in 2014 for the treatment of ovarian cancer with BRCA mutations validated PARP-1 as an anticancer target and established its clinical importan… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
153
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 167 publications
(154 citation statements)
references
References 171 publications
1
153
0
Order By: Relevance
“…Indeed, the levels of PARP1 itself may act as a biomarker with over-active PARP1 activity suggest that the tumour or leukemia may be responsive to PARP inhibition. Mutated BRCA is the most recognised and reliable biomarker for DNA repair deficiency but many others, including CDK12 and FA proteins, are also used in repair deficiency analysis [26]. Iniparib, was unsuccessful in a phase III trial when used as a treatment for triple-negative breast cancer [26].…”
Section: Non-homologous End Joiningmentioning
confidence: 99%
See 2 more Smart Citations
“…Indeed, the levels of PARP1 itself may act as a biomarker with over-active PARP1 activity suggest that the tumour or leukemia may be responsive to PARP inhibition. Mutated BRCA is the most recognised and reliable biomarker for DNA repair deficiency but many others, including CDK12 and FA proteins, are also used in repair deficiency analysis [26]. Iniparib, was unsuccessful in a phase III trial when used as a treatment for triple-negative breast cancer [26].…”
Section: Non-homologous End Joiningmentioning
confidence: 99%
“…Mutated BRCA is the most recognised and reliable biomarker for DNA repair deficiency but many others, including CDK12 and FA proteins, are also used in repair deficiency analysis [26]. Iniparib, was unsuccessful in a phase III trial when used as a treatment for triple-negative breast cancer [26]. It also proved to be ineffective in a phase II non-small lung cancer trial.…”
Section: Non-homologous End Joiningmentioning
confidence: 99%
See 1 more Smart Citation
“…13 PARP-1-mediated cell death, parthanatos, has been defined as a hallmark signature of neuronal cell death in Parkinson’s disease. 4 Additionally, PARP-1 has been shown to propagate the inflammatory cycle when hyperactivated by reactive oxygen species-induced DNA damage by rapidly catalyzing PAR which promotes NF-κB signal transduction.…”
Section: Introductionmentioning
confidence: 99%
“…1,5,6 However, these drugs are not CNS penetrant and are also cytotoxic because of the respective intrinsic anticancer mechanisms of each compound. 3 Recently, we demonstrated how the cytotoxic properties of olaparib can be greatly reduced when replacing piperazine with a 2,6-diazaspiro[3.3]heptane core; 7 however, the CNS uptake of this analogue is still under investigation. Therefore, it is important to understand why PARPis are not CNS penetrant and whether PARPis can be developed with reduced DNA damaging properties.…”
Section: Introductionmentioning
confidence: 99%